D.E. Shaw & Co
TMCI icon

D.E. Shaw & Co’s Treace Medical Concepts TMCI Stock Holding History

D.E. Shaw & Co’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
583,277
-257,992
-31% -$709K ﹤0.01% 3072
2026
Q1 		$1.13M Buy
841,269
+211,139
+34% +$421K ﹤0.01% 3361
2025
Q4 		$1.54M Sell
630,130
-131,203
-17% -$570K ﹤0.01% 3249
2025
Q3 		$5.11M Sell
761,333
-62,023
-8% -$405K ﹤0.01% 2191
2025
Q2 		$4.84M Sell
823,356
-96,818
-11% -$631K ﹤0.01% 2064
2025
Q1 		$7.72M Sell
920,174
-195,652
-18% -$1.76M 0.01% 1583
2024
Q4 		$8.3M Sell
1,115,826
-28,140
-2% -$188K 0.01% 1622
2024
Q3 		$6.64M Buy
1,143,966
+382,797
+50% +$2.46M 0.01% 1729
2024
Q2 		$5.06M Buy
761,169
+484,730
+175% +$3.92M ﹤0.01% 1839
2024
Q1 		$3.61M Buy
276,439
+129,863
+89% +$1.73M ﹤0.01% 2148
2023
Q4 		$1.87M Buy
146,576
+78,327
+115% +$791K ﹤0.01% 2720
2023
Q3 		$895K Sell
68,249
-172,714
-72% -$3.16M ﹤0.01% 3130
2023
Q2 		$6.16M Buy
240,963
+101,899
+73% +$2.63M 0.01% 1708
2023
Q1 		$3.5M Buy
+139,064
New +$3.27M ﹤0.01% 2248

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co's TMCI Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Treace Medical Concepts (TMCI) stake by 31% in Q2 2026, selling an estimated $709K and leaving 583,277 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3072.

D.E. Shaw & Co first reported a position in TMCI in Q1 2023 and has held it in 14 quarters since. The position peaked at $8.3M in Q4 2024. 117 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • D.E. Shaw & Co held 583,277 shares of Treace Medical Concepts worth $2.32M as of Q2 2026.
  • D.E. Shaw & Co sold 257,992 Treace Medical Concepts shares in Q2 2026, an estimated $709K.
  • Treace Medical Concepts made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3072 holding.
  • D.E. Shaw & Co first reported a position in Treace Medical Concepts in Q1 2023 and has held it in 14 quarters since.
  • D.E. Shaw & Co's Treace Medical Concepts position peaked at $8.3M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.